Celgene Corp. /de/, 10% Owner at Jounce Therapeutics, Inc. (JNCE), bought 3,456,463 shares at $16.00 ($10.0M) on 2017-02-01, disclosed to the SEC on 2017-02-01.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 2,831,463 | $0 | 0.0% |
| 2 | $16.00 | 625,000 | $10.0M | 100.0% |
| Total | $2.89 avg | 3,456,463 | $10.0M | 100% |
| Filing → |
| XLRN | BUY | 2019-01-22 | $30.4M | — | Filing → |
| AGIO | BUY | 2018-01-23 | $57.0M | — | Filing → |
| CRSP | SELL | 2017-12-07 | $19.6M | — | Filing → |